Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles
Noble Financial Capital Markets M.A.D. MAX Equity Conference
LAKE LAS VEGAS, Nev.--(BUSINESS WIRE)--The Noble Financial Capital Markets M.A.D. MAX Equity Conference takes place August 18, 2008 - August 19, 2008 at Loews Lake Las Vegas in Henderson. Listed below are the Noble Financial Capital Markets M.A.D. MAX Equity Conference presenter profiles. For in-depth information about the event, visit http://www.noblemadmax.com/madmaxhome.htm.
Business Wire is the official news wire for the Noble Financial Capital Markets M.A.D. MAX Equity Conference. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.
| Company: | 1-800-PetMeds |
| Ticker Symbol & Exchange: | PETS |
| Investor Relations Contact: | Bruce Rosenbloom |
| Investor Relations Contact Phone: | 954-979-5995 |
| Web: | www.1800petmeds.com |
| Date of Presentation: | 8/18/08 |
| PetMed Express, Inc. d/b/a 1-800-PetMeds, is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, ease of ordering and speed of delivery. | |
| The Company markets its products through national television, online, and direct mail/print advertising campaigns, which direct the consumers to order by phone or on the internet on its website at www.1800petmeds.com, and aim to increase the recognition of the “1-800-PetMeds” brand name. | |
| Company: | Access Pharmaceuticals, Inc. |
| Ticker Symbol & Exchange: | ACCP.OB |
| Investor Relations Contact: | Stephen B. Thompson |
| Investor Relations Contact Phone: | 214-905-5100 |
| Web: | www.accesspharma.com |
| Date of Presentation: | Monday, August 18, 2008 |
| Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, MuGard™ for the management of oral mucositis. The company’s lead oncology product is ProLindac™, a polymer-linked platinum cancer drug, which is in Phase 2 clinical testing in recurrent ovarian cancer patients. Angiolix® an antiangiogenic humanized monoclonal antibody, and Prodrax®, a hypoxia-activated prodrug, are the company’s lead preclinical oncology products. Access is also developing oral insulin and oral hGH using its proprietary Cobalamin™ oral drug delivery technology. | |
| Company: | Allion Healthcare |
| Ticker Symbol & Exchange: | ALLI | NASDAQ |
| Investor Relations Contact: | Rich Cockrell, The Cockrell Group |
| Investor Relations Contact Phone: | 404.942.3369 |
| Web: | www.allionhealthcare.com |
| Date of Presentation: | 08.18.08 |
| Allion Healthcare, Inc. is a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients as well as specialized biopharmaceutical medications and services to chronically ill patients. Allion Healthcare sells HIV/AIDS medications, ancillary drugs and nutritional supplies under the trade name MOMS Pharmacy. Allion Healthcare provides services for the intravenous immunoglobulin, Blood Clotting Factor and other therapies through its Biomed America division. Allion Healthcare works closely with physicians, nurses, clinics, AIDS Service Organizations, and with government and private payors to improve clinical outcomes and reduce treatment costs. | |
| Company: | Alphatec Spine, Inc. |
| Ticker Symbol & Exchange: | ATEC |
| Investor Relations Contact: | Cheryl Monblatt |
| Investor Relations Contact Phone: | 760 505 1785 |
| Web: | www.alphatecspine.com |
| Date of Presentation: | Monday, August 18 |
|
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company involved in the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, with a focus on treating disorders related to the aging spine. The company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The company is poised to achieve its goal through new solutions for patients with osteoporosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, Alphatec Spine also markets its spine products in Europe. |
|
| Company: | American CareSource Holdings, Inc. |
| Ticker Symbol & Exchange: | AMEX: XSI |
| Investor Relations Contact: | Melody Carey |
| Investor Relations Contact Phone: | 917-322-2571 |
| Web: | www.anci-care.com |
| Date of Presentation: | 8/18/2008 |
| American CareSource Holdings, the first national, publicly traded ancillary care network services company offers a comprehensive national network of approximately 2,500 ancillary service providers at over 25,000 sites. The Company's ancillary network and management provides a complete outsourced solution for a wide variety of healthcare payors and plan sponsors including self-insured employers, indemnity insurers, PPOs, HMOs, third party administrators and both federal and local governments. For additional information, please visit www.anci-care.com. | |
| Company: | Baldwin Technology Company, Inc. |
| Ticker Symbol & Exchange: | AMEX: BLD |
| Investor Relations Contact: | Helen P. Oster |
| Investor Relations Contact Phone: | 203 402 1004 |
| Web: | baldwintech.com |
| Date of Presentation: | 8/19/2008 |
| Baldwin is a leading global supplier of process automation systems and associated consumables for the printing and publishing industry. Baldwin's broad range of products are designed to enhance the quality, productivity and cost-efficiency of the print manufacturing process while addressing environmental concerns and safety issues. | |
| Baldwin sells its products both to printers to upgrade the quality and capability of their existing presses and to printing press manufacturers who incorporate them into their own equipment. | |
| Headquartered in Connecticut, Baldwin has product development and production facilities, as well as a network of sales and service operations, in strategic markets worldwide. | |
| Company: | Ballantyne of Omaha, Inc. |
| Ticker Symbol & Exchange: | AMEX: BTN |
| Investor Relations Contact: | Ratula Roy/David Collins |
| Investor Relations Contact Phone: | 212-835-8500 |
| Web: | roy@jcir.com |
| Date of Presentation: | Monday, Aug. 18, 2008; 11:30 a.m PT |
| For over 70 years, Ballantyne (BTN) has built a commanding position and strong customer relationships within the traditional cinema projection market. Now armed with NEC’s state-of-the art Starus™ digital projector line, BTN’s leading digital cinema service business and cinema screens and other products, BTN is ideally positioned to participate in the cinema industry’s largest-ever capital spending program: the conversion digital cinema technology. | |
| Company: | BioScrip, Inc. |
| Ticker Symbol & Exchange: | BIOS Nasdaq |
| Investor Relations Contact: | Craig Allison - Lisa Wilson |
| Investor Relations Contact Phone: | 914-460-1636 - 917-543-9932 |
| Web: | www.bioscrip.com |
| Date of Presentation: | 8/19/2008 |
| BioScrip is a specialty healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex healthcare conditions. | |
| Company: | BioSphere Medical, Inc. |
| Ticker Symbol & Exchange: | BSMD (NASDAQ) |
| Investor Relations Contact: | Kim Sutton Golodetz |
| Investor Relations Contact Phone: | 212-838-3777 |
| Web: | www.biospheremed.com |
| Date of Presentation: | 8/18/2008 |
| BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments. | |
| Company: | Bonds.com Group, Inc. |
| Ticker Symbol & Exchange: | (OTC:BDCG) |
| Investor Relations Contact: | Justin Davis |
| Investor Relations Contact Phone: | 877-800-BDCG (2324) |
| Web: | Justin.Davis@CirrusFC.com |
| Date of Presentation: | 8/19/2008 |
| Bonds.com Group, Inc., (OTC:BDCG) provides through its broker dealer subsidiary, Bonds.com, Inc., an online fixed income trading platform, BondStation. BondStation empowers self directed investors by providing a competitive centralized marketplace for the usually illiquid products such as Municipals, Corporates, Agencies, Emerging Market Debt, Structured Products and CD’s. The company differentiates itself by offering 30,000 unique securities from 175+ competing sources at no cost to its clients or liquidity providers. Market research, investor tools, and fixed income educational tools are provided at no fee to enhance the customer experience. Our goal is to empower clients with unbiased market information and execution capabilities. | |
| Company: | CBIZ, Inc. |
| Ticker Symbol & Exchange: | CBZ |
| Investor Relations Contact: | Lori Novickis |
| Investor Relations Contact Phone: | 216-525-1953 |
| Web: | www.cbiz.com |
| Date of Presentation: | 8/18/2008 |
| CBIZ, Inc. provides professional business services that help clients better manage their finances, employees and technology. As the largest benefits specialist, one of the largest accounting, valuation and medical practice management companies in the United States, CBIZ provides its clients with financial services which include accounting and tax, internal audit, merger and acquisition advisory, and valuation. Employee services include group benefits, property and casualty insurance, payroll, HR consulting and wealth management. CBIZ also provides information technology, hardware and software solutions, healthcare consulting and medical practice management. These services are provided throughout a network of more than 140 Company offices in 34 states. | |
| Company: | CombiMatrix Corporation |
| Ticker Symbol & Exchange: | CBMX (Nasdaq) |
| Investor Relations Contact: | Amit Kumar, President & CEO |
| Investor Relations Contact Phone: | 425-493-2000 |
| Web: | www.combimatrix.com |
| Date of Presentation: | 8/18/2008 |
| CombiMatrix Corporation is a biotechnology company headquartered near Seattle, Washington, USA, with a subsidiary, CombiMatrix Molecular Diagnostics, headquartered in Irvine, California. CombiMatrix's patented electrochemical manufacturing process utilizes standard semiconductor technology, proprietary software, and chemistry to build arrays of materials -- molecule by molecule. The company's CustomArray™ products are DNA microarrays, which have uses in pharmaceutical, biotech, and agrochemical industries as well as in research and government markets. The company also uses its technology in synergistic internal programs for diagnostics development, drug development, and biodefense in addition to partnerships for nanomaterials development. | |
| Company: | Continucare Corporation |
| Ticker Symbol & Exchange: | CNU:AMEX |
| Investor Relations Contact: | Fernando L. Fernandez |
| Investor Relations Contact Phone: | 305-500-2105 |
| Web: | www.continucare.com |
| Date of Presentation: | 8/19/2008 |
| Continucare provides primary care physician services on an outpatient basis through a network of medical facilities and independent physician affiliates (IPAs) in the State of Florida. Continucare has 18 medical offices equipped with state-of-the-practice technology and staffed with experienced physicians and a comprehensive support staff. In addition, Continucare provides health practice management services to IPAs who practice primary care medicine in South Florida. Continucare assists these physicians with medical utilization and pharmacy management and specialist network development, freeing them to devote more time to patient care. | |
| Company: | CSMG Technologies Inc. |
| Ticker Symbol & Exchange: | CTGI - OTCBB |
| Investor Relations Contact: | Michael Dodge |
| Investor Relations Contact Phone: | 212.495.0744 |
| Web: | www.csmgtechinternational.com |
| Date of Presentation: | 9/19/2008 |
| CSMG Technologies, Inc. is an advanced technology management company engaged in owning, developing, patenting, managing, licensing, and marketing. | |
| Live Tissue Connect Subsidiary | |
| LTC's 400 VAD System, used in human surgery to bond / weld soft tissue, replaces sutures, staples and glues, just received FDA clearance. | |
| Green Energy | |
| CSMG recently acquired Carbon Capture Technologies owns worldwide exclusive license to composition and method for use of novel Carbon Dioxide (CO2) recyclable adsorbent based on surface modified nanoporous silicas. Potential uses include C02 emissions from coal-fired power plants and surgical applications. | |
| CSMG’s landfill gas technology separates carbon dioxide and other impurities from gas produced in landfills. | |
| Company: | CTG |
| Ticker Symbol & Exchange: | Nasdaq: CTGX |
| Investor Relations Contact: | James R. Boldt, CEO |
| Investor Relations Contact Phone: | (716) 888-3634 |
| Web: | www.ctg.com |
| Date of Presentation: | Tuesday, August 19 |
| CTG provides IT solutions and services to help Global 2000 clients focus on their core businesses and use IT as a competitive advantage to excel in their markets. CTG combines in-depth understanding of our clients’ businesses with a full range of integrated services and proprietary ISO 9001:2000-certified service methodologies. Our 3,500 IT professionals based in an international network of offices in North America and Europe have a proven track record of delivering high-value, industry-specific solutions. | |
| Company: | Cytori Therapeutics, Inc. |
| Ticker Symbol & Exchange: | CYTX -- NASDAQ |
| Investor Relations Contact: | Tom Baker |
| Investor Relations Contact Phone: | 858-458-0900 |
| Web: | www.cytoritx.com |
| Date of Presentation: | 8/18/2008 |
| Cytori’s (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe and Asia Pacific into the reconstructive surgery market while the Celution® 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com | |
| Company: | EF Johnson Technologies, Inc. |
| Ticker Symbol & Exchange: | EFJI |
| Investor Relations Contact: | Jana Ahlfinger Bell |
| Investor Relations Contact Phone: | 972-819-0700 |
| Web: | www.efji.com |
| Date of Presentation: | 8/18/2008 |
| Headquartered in Irving, Texas, EF Johnson Technologies, Inc. focuses on innovating, developing and marketing the highest quality secure communications solutions to organizations whose mission is to protect and save lives. The Company’s customers include first responders in public safety and public service, the federal government, and industrial organizations. The Company’s products are marketed under the EFJohnson, 3e Technologies International, and Transcrypt International trade names. | |
| Company: | EMS Technologies, Inc. |
| Ticker Symbol & Exchange: | ELMG & NASDAQ |
| Investor Relations Contact: | Gary Shell |
| Investor Relations Contact Phone: | 770-729-6512 |
| Web: | http://www.ems-t.com/ |
| Date of Presentation: | Monday, August 18, 2008 |
| EMS Technologies, Inc. (NASDAQ: ELMG) is a wireless and satellite communication solutions leader, serving aeronautical, defense, maritime, commercial space and supply chain markets. Through its LXE, EMS SATCOM, and Defense & Space Systems divisions, EMS keeps people, systems and data connected, wherever they are -- on the ground, in the warehouse, in the air, or in space. The company is headquartered in Atlanta, employs approximately 1,000 people worldwide and operates major manufacturing facilities in Atlanta and Ottawa, Canada. | |
| Company: | Etelos, Inc. |
| Ticker Symbol & Exchange: | OTCBB: ETLO |
| Investor Relations Contact: | Leslie Green |
| Investor Relations Contact Phone: | 650-312-9060 |
| Web: | etelos.com |
| Date of Presentation: | 9:30 AM Aug. 19, 2008 |
| Etelos provides on-demand, customizable browser-based applications on the hosting environment you choose. Etelos' patent-pending technology for developing and deploying on-demand applications is revolutionizing the world of software distribution. The Etelos Marketplace gives developers an easy way to license, distribute and host applications. It also gives businesses a wide selection of fully customizable, on-demand applications to buy and deploy to the hosting environment of their choice. The Etelos Ecosystem provides all of the features of Software as a Service (SaaS) with all the flexibility of custom development. | |
| Company: | ev3 Inc. |
| Ticker Symbol & Exchange: | EVVV NASDAQ |
| Investor Relations Contact: | Julie Tracy Sr. Vice President |
| Investor Relations Contact Phone: | 949-680-1375 |
| Web: | http://www.ev3.net |
| Date of Presentation: | 8/18/2008 |
| Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of lower extremity vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net. | |
| Company: | Exactech |
| Ticker Symbol & Exchange: | Nasdaq EXAC |
| Investor Relations Contact: | Hawk Associates |
| Investor Relations Contact Phone: | Julie Marshall 305.451.1888 |
| Web: | www.hawkassociates.com and www.exac.com |
| Date of Presentation: | 8/18/2008 |
| Exactech is a pure play orthopaedic competitor that is gaining market share in the rapidly expanding global biomedical device industry. The company's products are used in the restoration of bones and joints that have deteriorated as a result of injury or disease such as arthritis. | |
| Exactech develops, manufactures, markets, distributes and sells its orthopaedic implant devices, including knee, shoulder, and hip implant systems, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally in over 30 countries. | |
| Founded and led by an orthopaedic surgeon, the company has built its success on its customer-centric culture. Feedback and input from its surgeon customers have helped Exactech develop a pipeline of innovative products that improve patient outcomes. | |
| Company: | EXL Service |
| Ticker Symbol & Exchange: | EXLS |
| Investor Relations Contact: | Jarrod Yahes |
| Investor Relations Contact Phone: | jarrod.yahes@exlservice.com 212.277.7109 |
| Web: | www.exlservice.com |
| ExlService Holdings, Inc. (Nasdaq: EXLS - News) is a leading provider of Outsourcing and Transformation Services. EXL’s Outsourcing Services include a full spectrum of business process outsourcing services from offshore delivery centers requiring ongoing process management skills. Transformation Services enable continuous improvement of client processes by bringing together EXL’s capabilities in reengineering including Six Sigma process improvement, research & analytics, and risk advisory services. Headquartered in New York, EXL primarily serves the needs of Global 1000 companies in the insurance, utilities, financial services, healthcare, telecommunications and transportation sectors. Find additional information about EXL at www.exlservice.com. | |
| Company: | Full House Resorts |
| Ticker Symbol & Exchange: | FLL-AMEX |
| Investor Relations Contact: | Mark Miller |
| Investor Relations Contact Phone: | 702-221-7800 |
| Web: | http://www.fullhouseresorts.com/ |
| Date of Presentation: | Monday, August 18, 2008 12 pm PT |
| Full House owns, develops and manages gaming facilities. Full House owns the Stockman’s Casino in Fallon, Nevada which has 8,400 square feet of gaming space with approximately 260 gaming machines, four table games and a keno game. The Company also receives a guaranteed fee from the operation of Harrington Raceway and Casino in Harrington, Delaware. Full House also has a management agreement with the Nottawaseppi Huron Band of Potawatomi Indians for the development and management of a first-class casino/resort with 2,500 gaming devices, 90 table games and 20 poker tables in the Battle Creek, Michigan area – currently under construction. | |
| Company: | Globex Mining Enterprises Inc. |
| Ticker Symbol & Exchange: | GMX-TSX, GLBXF-OTCQX |
| Investor Relations Contact: | Dan Symons from Renmark |
| Investor Relations Contact Phone: | 514-939-3989, ext. 3323 |
| Web: | www.globexmining.com |
| Date of Presentation: | August 19th, 2008 |
|
Globex is a TSX listed Canadian royalty and exploration company with a vast portfolio of wholly owned projects all within North America. The company has few shares issued, cash in the bank and no debt. The first quarter of 2008 saw the stat of significant royalty streams as two mines reached production. Six others are in pre-production or due diligence. Projects include: copper, zinc, gold, magnesium, talc, nickel, platinum, palladium, uranium, rare earths and diamonds. |
|
| Company: | iLinc |
| Ticker Symbol & Exchange: | ILC |
| Investor Relations Contact: | James L. Dunn, Jr. |
| Investor Relations Contact Phone: | 602-952-1200 |
| Web: | www.ilinc.com |
| Date of Presentation: | 8/19/2008 |
| iLinc, a recognized leader in web conferencing, desktop video conferencing software and collaboration solutions, aims to revolutionize the way organizations meet and communicate. Through its software and services, iLinc liberates people by enabling them to get more done, travel less, achieve work-life balance while preserving the environment. iLinc offers the only enterprise-class web and video conferencing software that allows customers to choose between a software-as-a-service (SaaS) rental model or a traditional software purchase model, in combination with hosting by iLinc or on-premise installation. iLinc is headquartered in Phoenix, Arizona. For more visit www.ilinc.com/investors. | |
| Company: | Inspire Pharmaceuticals |
| Ticker Symbol & Exchange: | ISPH |
| Investor Relations Contact: | Jenny Kobin |
| Investor Relations Contact Phone: | 919 287-1219 |
| Web: | www.inspirepharm.com |
| Date of Presentation: | 8/18/2008 |
| Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is currently developing products for dry eye, cystic fibrosis and glaucoma. Elestat, Restasis and Prolacria are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com. | |
| Company: | KRATOS DEFENSE & SECURITY SOLUTIONS, INC |
| Ticker Symbol & Exchange: | NASDAQ: KTOS |
| Investor Relations Contact: | MICHAEL BAEHR, VP of IR |
| Investor Relations Contact Phone: | (858) 812-7366 |
| Web: | WWW.KRATOSDEFENSE.COM |
| Date of Presentation: | AUG. 18 |
| Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS) is a leading national defense, information technology and homeland security solutions provider. The Company primarily performs work for the U.S. federal government, but also for various state and local agencies. Principle services include C5ISR, weapon systems life cycle support, military range operations and technical services, missile, rocket and weapon systems test & evaluation, advanced network engineering and IT services, security and surveillance integration, and critical infrastructure design and integration. The Company is headquartered in San Diego, California, with resources throughout the U.S. and at key strategic military locations. | |
| Company: | MediaNet Group Technologies, Inc. |
| Ticker Symbol & Exchange: | (OTCBB: MEDG) |
| Investor Relations Contact: | Martin Berns |
| Investor Relations Contact Phone: | 954-974-5818 ext. 202 |
| Web: | www.medianetgroup.com |
| Date of Presentation: | 8/19/08 12:30 p.m. PST |
| MediaNet Group Technologies, Inc. (OTCBB: MEDG), through its BSP Rewards division, has developed the Internet’s largest mall and affinity program platform. BSP builds, brands, customizes and administers proprietary loyalty/rewards/mall programs for each client and organization and is also a value added element layered onto debit and stored value cards. BSP Rewards creates private branded versions of the mall for clients that enroll their database of members and they then promote the mall to their members. Benefits to clients include customer acquisition, incentive and retention, loyalty programs, enhanced sales and potential new and recurring revenue—turning operational costs into profit centers. | |
| Company: | Merit Medical Systems, Inc. |
| Ticker Symbol & Exchange: | NASDAQ: MMSI |
| Investor Relations Contact: | Anne-Marie Wright |
| Investor Relations Contact Phone: | (801) 208-4167 |
| Web: | www.merit.com |
| Date of Presentation: | 8/18/2008 |
| Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 90 individuals. Merit employs approximately 1,600 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland. | |
| Company: | Misonix, Inc. |
| Ticker Symbol & Exchange: | Nasdaq: MSON |
| Investor Relations Contact: | Kevin McGrath |
| Investor Relations Contact Phone: | 212-245-4577 |
| Web: | www.misonix.com |
| Date of Presentation: | August 19, 2008 at 8:30am PT |
| Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. These devices include High Intensity Focused Ultrasound for the treatment of tumors, soft tissue aspirators, laparoscopic cutting and coagulation instruments, and surgical aspirators. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, spinal surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. | |
| Company: | MTR Gaming |
| Ticker Symbol & Exchange: | (NASDAQ:MNTG) |
| Investor Relations Contact: | Melissa Dixon |
| Investor Relations Contact Phone: | 212-836-9613 |
| Web: | www.mtrgaming.com |
| Date of Presentation: | 8/18/2008 |
| MTR Gaming Group, Inc., through subsidiaries, owns and operates Mountaineer Casino, Racetrack & Resort in Chester, WV; Presque Isle Downs & Casino in Erie, PA; and Scioto Downs in Columbus, OH. The Company also owns a 90% interest in Jackson Trotting Association, LLC, which operates Jackson Harness Raceway in Jackson, MI, and a 50% interest in the North Metro Harness Initiative, LLC, which operates Running Aces Harness Park in Minneapolis, MN. Running Aces Harness Park racetrack commenced racing in April 2008 and opened a 50-table card room on June 30, 2008. For more information, please visit www.mtrgaming.com. | |
| Company: | National Lampoon |
| Ticker Symbol & Exchange: | NLN AMEX |
| Investor Relations Contact: | Howard Gostfriend |
| Investor Relations Contact Phone: | 305-918-7000 |
| Web: | info@amcapventures.com |
| Date of Presentation: | 8/18/2008 |
| National Lampoon, Inc. has been a dominant force in the comedy world for almost 40 years, and is currently active in a broad array of media and entertainment segments. These include feature films, Internet and online entertainment, television programming, home video, audio, and book publishing. The Company also owns interests in all major National Lampoon properties, including National Lampoon’s Animal House, the National Lampoon Vacation series and National Lampoon’s Van Wilder. National Lampoon reaches nearly one in four of all 18 to 24 year old college students in America today. These include the National Lampoon Humor Network - the most trafficked humor sites on the web, the Drunk University Network, the new ZAZ Network, and the National Lampoon Video Network, which includes channels on YouTube, Yahoo, Veoh, and Lycos. | |
| Company: | Neogenomics, Inc. |
| Ticker Symbol & Exchange: | OTCBB: NGNM |
| Investor Relations Contact: | Neogenomics |
| Investor Relations Contact Phone: | Steven Jones - (239) 325-2001 |
| Web: | www.neogenomics.org |
| Date of Presentation: | Monday, Aug. 18, 2008 1:30 p.m. |
| NeoGenomics, is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics also has labs in Nashville, Tenn. and Irvine, Calif. and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. | |
| Company: | Novelos Therapeutics, Inc. |
| Ticker Symbol & Exchange: | NVLT OTCBB |
| Investor Relations Contact: | Stephen Lichaw |
| Investor Relations Contact Phone: | 201-240-3200 |
| Web: | www.novelos.com |
| Date of Presentation: | August 18, 2008, 11am PDT |
| Novelos is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds completed clinical trials in humans and were approved in Russia where they were originally developed. | |
| Company: | OmniComm Systems, Inc. |
| Ticker Symbol & Exchange: | OMCM.OB |
| Investor Relations Contact: | Ronald Linares, CFO |
| Investor Relations Contact Phone: | Ronald Linares, CFO 954-473-1254 |
| Web: | www.omnicomm.com |
| Date of Presentation: | Tuesday, August 19, 2008 at 7:30 AM |
| OmniComm Systems, Inc. is an eClinical software and services company dedicated to helping pharmaceutical, biotechnology, CRO, research and medical device organizations to maximize the value of their clinical research investments through the use of innovative and progressive technologies. The company has corporate headquarters located in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas. Founded in 1997, with a systems integration focus and an EDC solution built for clinical research conducted at Mt. Sinai Hospital, we have continued to develop our product pipeline and services to meet the evolving needs of the drug development marketplace. | |
| Company: | PHC, Inc. d/b/a Pioneer Behavioral Healt |
| Ticker Symbol & Exchange: | AMEX: PHC |
| Investor Relations Contact: | Liolios Group |
| Investor Relations Contact Phone: | (949) 574-3860 |
| Web: | www.phc-inc.com |
| Date of Presentation: | August 19 at 7:30 a.m. Pacific Time |
| PHC, Inc. d/b/a Pioneer Behavioral Health is an emerging national healthcare company providing behavioral health services through contracts with government agencies, national insurance companies, as well as major transportation and gaming companies. | |
| Pioneer to helps people gain and maintain physical, spiritual and emotional health. The company achieves this by developing and delivering the highest quality, most culturally responsive, compassionate and competitive services to individuals, corporations, and the community. | |
| Pioneer operates in three complementary business operating units: hospital and clinical services; integrated delivery services; and clinical research. | |
| Company: | Pipex Pharmaceuticals, Inc. |
| Ticker Symbol & Exchange: | AMEX: PP |
| Investor Relations Contact: | Thomas Redington |
| Investor Relations Contact Phone: | 203-222-7399 |
| Web: | www.pipexinc.com |
| Date of Presentation: | 8/18/2008 |
| Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of central nervous system (CNS) and autoimmune diseases. Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and to complete the further clinical testing, manufacturing and regulatory requirements and seek marketing authorizations. Pipex is focused on treating Dry Age-Related Macular Degeneration (AMD), multiple sclerosis (MS), Rheumatoid Arthritis (RA) and fibromyalgia. | |
| Company: | Pluristem Therapeutics, Inc. |
| Ticker Symbol & Exchange: | PSTI: NASDAQ |
| Investor Relations Contact: | William R. Prather RPh, MD |
| Investor Relations Contact Phone: | 303-883-4954 |
| Web: | Pluristem.com |
| Date of Presentation: | 8/19/2008 |
| Pluristem Therapeutics Inc. is dedicated to the commercialization of non-personalized (allogeneic) cellular therapeutics for degenerative, ischemic and autoimmune indications. The Company’s pipeline of products, stored ready-to-use and without HLA matching needed, are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. | |
| These placental cells are expanded in the Company's proprietary PluriXTM 3D bioreactor, emulating bone-marrow, and not requiring supplemental growth factors. Pluristem believes that the resultant PLX (PLacental eXpanded) cells are able to differentiate into a variety of cell types. | |
| Pluristem’s first product, PLX-PAD, to treat limb ischemia, enters human trials in the fall of 2008. | |